1. A PHASE 1/1B DOSE‐ESCALATION TRIAL EVALUATING CPI‐818, AN ORAL INTERLEUKIN‐2‐INDUCIBLE T‐CELL KINASE INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL LYMPHOMA. (12th June 2019) Authors: Mobasher, M.; Miller, R.; Janc, J.; Kwei, L.; Barker, C.; Mohammady, A.; Luciano, G.; Radeski, D.; Kim, Y.; Khodadoust, M.; Horwitz, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A SELECTIVE AND COVALENT INHIBITOR OF ITK BLOCKS TCR SIGNALING, INHIBITS PROLIFERATION OF HUMAN SÉZARY CELLS IN VITRO, AND INDUCES TUMOR REGRESSION IN DOGS WITH T‐CELL LYMPHOMA. (12th June 2019) Authors: Buggy, J.J.; Ng, P.P.; Janc, J.W.; Hotson, A.; Hill, C.M.; Thamm, D.H.; Kim, Y.H.; Khodadoust, M.; Mobasher, M.; Miller, R.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019) Authors: Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; Pinilla‐Ibarz, J.; Opat, S.; Sivcheva, L.; Le Dû, K.; Fogliatto, L.M.; Utoft Niemann, C.; Weinkove, R.; Robinson, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗